Last reviewed · How we verify

NCT05189847: KAMMA

Clinical Register Studying the therApeutic Patient Population With Multifocal Atherosclerosis

Completed Last updated 26 June 2024
What this trial tests

trial in Polyvascular Disease in 3,059 participants. Completed in 31 January 2024.

Timeline
1 February 2022
Primary endpoint
31 January 2024
31 January 2024

Quick facts

Lead sponsorEurasian Association of Therapists
StatusCompleted
Study typeOBSERVATIONAL
Enrollment3,059
Start date1 February 2022
Primary completion31 January 2024
Estimated completion31 January 2024
Sites1 location across Russia

Conditions studied

Sponsor

Eurasian Association of Therapists

Who can join

18 and older, any sex, with Polyvascular Disease or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Аn international, multicenter, non-interventional real-life clinical practice Register studying the Actual therapeutic patient population with Multifocal Atherosclerosis in the Russian Federation and Eurasian countries

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Polyvascular Disease

Currently open trials in the same condition.

Other Eurasian Association of Therapists trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05189847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing